MTOR and cancer: Several molecularly targeted therapies have been licensed since the last gap analysis including lapatinib and pertuzumab in HER2+ cancers [31] and the mTOR inhibitor everolimus in ER+ve disease [72,256], which can overcome endocrine resistance [257].